瑞舒伐他汀对急性冠脉综合征血脂和高敏C反应蛋白的影响  

Effects of high dose rosuvastatin on plasma lipid level and hypersensitive C reaction protein(hs-CRP) in patients with acute coronary syndrome

作　　者：蒋建东[1] 陈燕春[1] 陆俊杰[1] 杨松[1] 

机构地区：[1]江苏省宜兴市人民医院心血管内科,江苏宜兴214200

出　　处：《海南医学院学报》2012年第12期1698-1700,1707,共4页Journal of Hainan Medical University

基　　金：江苏大学临床医学科研基金项目(JLY2010035)~~

摘　　要：目的:观察不同剂量瑞舒伐他汀治疗急性冠脉综合征患者血脂和高敏C反应蛋白的疗效及安全性。方法:82例急性冠脉综合征患者随机分为A组(瑞舒伐他汀20mg/d,n=41)和B组(瑞舒伐他汀10mg/d,n=41);观察4周后两组血脂、hs-CRP水平和不良反应发生率等指标变化。结果:4周后A组、B组的LDL-C水平较治疗前均有显著下降,分别为(2.67±0.94 vs.2.13±0.64;P=0.005)、(2.68±0.77 vs.2.37±0.58;P=0.044),但两组的LDL-C达标率差异有统计学意义(70.1%vs.43.9%,P=0.014),治疗后hs-CRP水平小于10mg/L的比例两组差异有统计学意义(85.4%vs.58.5%,P=0.007),试验中两组均未发现与药物相关的严重不良反应事件。结论:瑞舒伐他汀20mg/d能更显著降低急性冠脉综合征患者血脂与高敏C反应蛋白水平,且具有良好的耐受性和安全性。Objective： To observe the influcence of rosuvastatin on plasma lipid level and hypersensitive C-reaction protein（hs-CRP） in patients with acute coronary syndrome and and its safety.Methods：A total of 82 patients with ACS were randomly divided into group A and group B.Group A were treated with rosuvastatin 20 mg/d（high dose） and group B treated with rosuvastatin 10 mg/d（routine dose）,The lipid and hs-CRP level and adverse events were compared after 4 weeks.Results：After 4 weeks of treatment,LDL-C in both group A（2.67±0.94 vs 2.13±0.64;P=0.005） and group B（2.68±0.77 vs 2.37±0.58;P=0.044） decreased significantly,but more patients in group A resorted target LDL-C level than that in group B（70.1% vs 43.9%;P=0.014）.Besides,the rate of patients showing hs-CRP less than 10 mg/L were significant different between the two groups（85.4% vs 58.5%;P=0.007）.No drug-related serious adverse events occurred during the study.Conclusion： Rosuvastatin at the dosage of 20 mg/day can significantly reduce LDL-C and hs-CRP level in patients with acute coronary syndrome showing good tolerance and safety.

关 键 词：瑞舒伐他汀 急性冠脉综合征 血脂 高敏C反应蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]